Skip to content

Addiction research published in 2016

33 studies whose primary subject is addiction were published in 2016, up from 22 in 2015. Newest first. Back to the addiction overview

Studies

Salience attribution and its relationship to cannabis-induced psychotic symptoms.

Psychological Medicine December 2016 Michael Bloomfield, E Mouchlianitis, C J A Morgan et al.

Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. We tested 17 cannabis users and 17 age- and...

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.

Journal of Psychopharmacology November 15, 2016 Clinton E. Canal, Kevin S. Murnane

Classic hallucinogens share pharmacology as serotonin 5-HT 2A , 5-HT 2B , and 5-HT 2C receptor agonists. Unique among most other Schedule 1 drugs, they are generally non-addictive and can be effective tools in the treatment of addiction. Mechanisms underlying these attributes are largely unknown. However, many preclinical studies show that 5-HT 2C agonists counteract the addictive effects of...

Psychedelics as Medicines: An Emerging New Paradigm

Clinical Pharmacology & Therapeutics November 4, 2016 De Nichols, Mw Johnson, Cd Nichols 366 citations

Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT 2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that...

Psychological and neuropsychological assessment of regular hoasca users.

Comprehensive Psychiatry November 1, 2016 Paulo César Ribeiro Barbosa, Rick J. Strassman, Dartiu Xavier Da Silveira et al. 104 citations

Hoasca (also called ayahuasca) is a N,N-dimethyltryptamine (DMT) - containing psychedelic brew originally used for magico-religious purposes by Amerindian populations of the Amazon Basin. Recently, Brazilian syncretic churches have helped spread the ritual use of hoasca to Western societies. The aim of this study was to evaluate substance use, and neuropsychological and psychological...

Efficacy of mindfulness-based addiction treatment (MBAT) for smoking cessation and lapse recovery: A randomized clinical trial.

Journal of Consulting and Clinical Psychology September 1, 2016 Jennifer Irvin Vidrine, Claire Adams Spears, Whitney L Heppner et al.

Objective: To compare the efficacy of Mindfulness-Based Addiction Treatment (MBAT) to a Cognitive Behavioral Treatment (CBT) that matched MBAT on treatment contact time, and a Usual Care (UC) condition that comprised brief individual counseling. Method: Participants (N = 412) were 48.2% African American, 41.5% non-Latino White, 5.4% Latino, and 4.9% other, and 57.6% reported a total annual...

DOI: 10.1037/ccp0000117 (opens in new tab) Full text (opens in new tab) Mindfulness Humans Treatment outcome Combined modality therapy +5

Ibogaine for treating drug dependence. What is a safe dose?

Drug and Alcohol Dependence September 1, 2016 Leo J. Schep, Robin J Slaughter, S Galea et al. 30 citations

The indole alkaloid ibogaine, present in the root bark of the West African rain forest shrub Tabernanthe iboga, has been adopted in the West as a treatment for drug dependence. Treatment of patients requires large doses of the alkaloid to cause hallucinations, an alleged integral part of the patient's treatment regime. However, case reports and case series continue to describe evidences of...

DOI: 10.1016/j.drugalcdep.2016.07.005 (opens in new tab) Full text (opens in new tab) Drug dependence Qt prolongation Ibogaine treatment ibogaine Current ibogaine doses +6

It’s time to take psilocybin seriously as a possible treatment for substance use disorders

The American Journal of Drug and Alcohol Abuse August 24, 2016 Michael P. Bogenschutz 18 citations

In the current issue of the American Journal of Drug and Alcohol Abuse, Johnson et al. (1) provide long-term outcome data from a smoking cessation pilot study of a treatment model using 2–3 doses o...

DOI: 10.1080/00952990.2016.1200060 (opens in new tab) Psilocybin Substance use Substance abuse treatment Hallucinogen

Psilocybin for treating substance use disorders?

Expert Review of Neurotherapeutics August 10, 2016 Bas T.h. de Veen, Arnt Schellekens, Michel M. M. Verheij et al. 102 citations

Evidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and...

Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys.

Drug and Alcohol Dependence August 1, 2016 Lance R Mcmahon

Cannabidiol, a therapeutic with potential serotonin (5-hydroxytryptamine; 5-HT) 5-HT1A receptor agonist activity, is the second most prevalent cannabinoid in Cannabis after Δ(9)-THC. The extent to which cannabidiol modifies the effects of Δ(9)-THC has not been firmly established, especially with respect to abuse-related effects in rhesus monkeys where previously antagonistic interactions have...

Mindfulness training applied to addiction therapy: insights into the neural mechanisms of positive behavioral change

Neuroscience and Neuroeconomics July 1, 2016 Eric L Garland, Matthew O. Howard, Sarah E. Priddy et al. 12 citations

Abstract: Dual-process models from neuroscience suggest that addiction is driven by dysregulated interactions between bottom-up neural processes underpinning reward learning and top-down neural functions subserving executive function. Over time, drug use causes atrophy in prefrontally mediated cognitive control networks and hijacks striatal circuits devoted to processing natural rewards in...

DOI: 10.2147/nan.s89257 (opens in new tab) Mindfulness Addiction Psychotherapist Behavioral therapy +2

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Journal of Psychopharmacology July 1, 2016 Deborah C. Mash, Barbara Ameer, Delphine Prou et al. 29 citations

This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of...

DOI: 10.1177/0269881116641331 (opens in new tab) Full text (opens in new tab) Cns drugs Blood–brain barrier Conditioned place preference Drug brain penetration +5

Meditation Awareness Training for the Treatment of Sex Addiction: A Case Study.

Journal of Behavioral Addictions June 27, 2016 William van Gordon, Edo Shonin, Mark D Griffiths

Background Sex addiction is a disorder that can have serious adverse functional consequences. Treatment effectiveness research for sex addiction is currently underdeveloped, and interventions are generally based on the guidelines for treating other behavioral (as well as chemical) addictions. Consequently, there is a need to clinically evaluate tailored treatments that target the specific...

Mindfulness meditation–based pain relief: a mechanistic account

Annals of the New York Academy of Sciences June 1, 2016 Fadel Zeidan, David R. Vago 304 citations

Pain is a multidimensional experience that involves interacting sensory, cognitive, and affective factors, rendering the treatment of chronic pain challenging and financially burdensome. Further, the widespread use of opioids to treat chronic pain has led to an opioid epidemic characterized by exponential growth in opioid misuse and addiction. The staggering statistics related to opioid use...

Evaluation of Yoga for Preventing Adolescent Substance Use Risk Factors in a Middle School Setting: A Preliminary Group-Randomized Controlled Trial.

Journal of Youth and Adolescence May 31, 2016 Bethany Butzer, Amanda LoRusso, Sunny H Shin et al.

Adolescence is a key developmental period for preventing substance use initiation, however prevention programs solely providing educational information about the dangers of substance use rarely change adolescent substance use behaviors. Recent research suggests that mind-body practices such as yoga may have beneficial effects on several substance use risk factors, and that these practices may...

Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Translational Psychiatry May 31, 2016 Maarten Belgers, M Leenaars, Judith R. Homberg et al. 64 citations

Ibogaine is a naturally occurring substance which has been increasingly used in the lay-scene to reduce craving and relapse in patients with substance use disorders (SUDs). Although human clinical trials on the safety and efficacy of ibogaine are lacking, animal studies do support the efficacy of ibogaine. In this systematic review and meta-analysis (MA), we summarise these animal findings,...

DOI: 10.1038/tp.2016.71 (opens in new tab) Full text (opens in new tab) Ibogaine Addiction treatment Drug self-administration reduction Curbing addictive behaviors +11

Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans

Journal of Psychoactive Drugs May 26, 2016 Amanda Amorin Nunes, Rafael G. Dos Santos, Flávia de Lima Osório et al. 92 citations

Recently, the anti-addictive potential of ayahuasca, a dimethyltryptamine(DMT)- and β-carboline-rich hallucinogenic beverage traditionally used by indigenous groups of the Northwest Amazon and currently by syncretic churches worldwide, has received increased attention. To better evaluate this topic, we performed a systematic literature review using the PubMed database to find quantitative...

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants

Frontiers in Neuroscience April 19, 2016 Cristina Miliano, Giovanni Serpelloni, Claudia Rimondo et al. 195 citations

New psychoactive substances (NPS) are a heterogeneous and rapidly evolving class of molecules available on the global illicit drug market (e.g smart shops, internet, "dark net") as a substitute for controlled substances. The use of NPS, mainly consumed along with other drugs of abuse and/or alcohol, has resulted in a significantly growing number of mortality and emergency admissions for...

DOI: 10.3389/fnins.2016.00153 (opens in new tab) MDMA Addiction Synthetic cannabinoids Neuropharmacology +5

Neurochemical substrates of the rewarding effects of MDMA: implications for the development of pharmacotherapies to MDMA dependence.

Behavioural Pharmacology April 2016 Concepción Roger-Sánchez, María P García-Pardo, Marta Rodríguez‐arias et al.

In recent years, studies with animal models of reward, such as the intracranial self-stimulation, self-administration, and conditioned place preference paradigms, have increased our knowledge on the neurochemical substrates of the rewarding effects of 3,4-methylenedioxymetamphetamine (MDMA) in rodents. However, pharmacological and neuroimaging studies with human participants are scarce....

Restructuring reward processing with Mindfulness-Oriented Recovery Enhancement: novel therapeutic mechanisms to remediate hedonic dysregulation in addiction, stress, and pain.

Annals of the New York Academy of Sciences April 1, 2016 Eric L Garland 136 citations

Though valuation processes are fundamental to survival of the human species, hedonic dysregulation is at the root of an array of maladies, including addiction, stress, and chronic pain, as evidenced by the allostatic shift in the relative salience of natural reward to drug reward observed among persons with severe substance use disorders. To address this crucial problem, novel interventions are...